New myelofibrosis drug tested in patients with liver issues
NCT ID NCT07480824
First seen Mar 23, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This early-stage study is testing a drug called TQ05105 in people with mild or moderate liver impairment and healthy volunteers. The goal is to see how the liver affects the drug's levels in the body and check for safety. 24 participants will receive a single dose and be monitored closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITINGLuoyang, Henan, 471000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
NOT_YET_RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQ05105 (a JAK/ROCK inhibitor drug)
What this could lead to
If successful, this study could help determine safe dosing of TQ05105 for people with liver problems who have myelofibrosis.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so results may not apply broadly. The drug may still cause side effects or not work as expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.